Press Releases

Leadership team additions
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]


January 25, 2022

JP Morgan Health Care Conference banner
Atomwise Invited to Present at the 2022 J.P. Morgan Healthcare Conference

Leading AI-pharma company among select few private companies to participate San Francisco, CA – January 5, 2022 – Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference. […]


January 5, 2022
Atomwise and GC Pharma partnership
GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

The partnership will develop new drug programs that advance GC Pharma’s global leadership in hemophilia and additional disease areas SAN FRANCISCO & YONGIN, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross […]

Atomwise sign in office
Atomwise Raises $123 Million in Series B Financing Co-Led by B Capital Group and Sanabil

New financing will enable Atomwise to further scale the largest artificial intelligence (AI)-driven drug discovery portfolio in history and expand $5 billion+ deal pipeline for small molecule drug discovery SAN FRANCISCO — August 11, 2020 — Atomwise, the company deciphering human disease via the largest AI-drug discovery portfolio, announced today that it has closed $123 […]

Atomwise #AI4COVID
Atomwise Partners with Global Research Teams to Pursue Broad-Spectrum Treatments Against COVID-19 and Future Coronavirus Outbreaks

Atomwise democratizes access to its advanced AI technology with 15 research collaborations underway to enable academic researchers to discover novel therapies for this pandemic and those in the future. SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it has fifteen research collaborations underway with leading global […]

Hansoh Expands AI Partnership with Atomwise after Early Success for Key Target in Therapy-Evading Cancers

Atomwise and Hansoh successfully identified potent hit compounds each having unique composition of matter for their first AI discovery program against drug-resistant oncology targets SHANGHAI & SAN FRANCISCO–(BUSINESS WIRE)– Hansoh Pharma (3692:HK), a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the expansion of their strategic partnership for […]

Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise to Expand Pellino Inhibitor Pipeline

The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications, including inflammation SAN FRANCISCO & SEONGNAM, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, announced today a research collaboration to launch […]